BOSTON, March 21 /PRNewswire/ -- PAREXEL International Corporation , a leading global bio/pharmaceutical services organization, today announced that Dr. Matthias Grossmann, M.D., Ph.D., and Dr. James Wong, Ph.D., have joined the Company's International Clinical Pharmacology Network. Dr. Grossmann and Dr. Wong, who are providing consultation to clients sponsoring early phase clinical trials across a broad range of therapeutic areas, have both been appointed to the position of Vice President, Clinical Pharmacology Consulting Services.
"With more innovation across the bio/pharmaceutical industry driving new compounds into clinical research, clients are increasingly turning to us for a combination of deep scientific knowledge and drug development experience," said Dr. Herman Scholtz, M.D., Corporate Vice President and Worldwide Head, Clinical Pharmacology, PAREXEL. "The wealth of therapeutic and clinical pharmacology expertise that Dr. Grossmann and Dr. Wong bring will further strengthen PAREXEL's support of clients in their early phase clinical development programs."
Dr. Grossmann is a clinical pharmacologist with extensive experience in early drug development research, particularly in cardiopulmonary physiology and pharmacology. Prior to joining PAREXEL, Dr. Grossmann was Managing Director and Head of Medical Affairs at a clinical pharmacology research group based in Mannheim, Germany. Previously, he held clinical pharmacology research positions at Charite Hospital in Berlin, Germany, the University of Texas Health Science Center at San Antonio, and the Stanford University School of Medicine in California. Dr. Grossmann holds an M.D. from Humboldt University in Berlin and a Ph.D. in clinical pharmacology from Technische University in Dresden. He has been Board Certified in clinical pharmacology, clinical physiology and pathophysiology. Dr. Grossmann has been an associate professor at the Technische University's Institute of Clinical Pharmacology since 2000. He has authored numerous scientific papers in the areas of clinical pharmacology, pharmacogenetics, and cardiology.
Dr. Wong joined PAREXEL from The Medicines Company where he was Director of Clinical Pharmacology, leading global teams in early drug development. Previously, he held senior positions in clinical pharmacology and pharmacokinetics at AstraZeneca and Schering AG. A trained pharmacist with a broad range of therapeutic expertise, including cardiology, oncology, dermatology, and central nervous system (CNS), Dr. Wong has been involved in the development of various well-known compounds. Dr. Wong holds a B. Pharm. from the School of Pharmacy at the University of London, a M.Sc. from King's Chelsea College of Pharmacy at the University of London, and a Ph.D. from the College of Pharmacy at the University of Texas, Austin. He has held teaching positions in clinical pharmacy, biopharmaceutical analysis, and pharmaceutical chemistry. Dr. Wong is a long-standing member of several professional associations, including the American Association of Pharmaceutical Scientists and the Royal Pharmaceutical Society of Great Britain. He has given several presentations and has authored papers on the subjects of clinical pharmacy, pharmacokinetics, and pharmacodynamics.
Dr. Grossmann is based at PAREXEL's Clinical Pharmacology Research Unit in Berlin, Germany and Dr. Wong is based at the Baltimore, Maryland Unit. PAREXEL's other Clinical Pharmacology Research Units are located throughout Southern California, in London and in Bloemfontein and George, South Africa.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and integration services. Headquartered near Boston, Massachusetts, PAREXEL operates in 56 locations throughout 43 countries around the world, and has over 6,215 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2006 as filed with the SEC on February 9, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Contacts: Jennifer Baird Rebecca Passo Director of Public Relations SHIFT Communications PAREXEL International Tel: +617-681-1217 Tel: +781-434-4409 Email: rpasso@shiftcomm.com Email: Jennifer.Baird@PAREXEL.com
PAREXEL InternationalCONTACT: Jennifer Baird, Director of Public Relations of PAREXELInternational, +1-781-434-4409, Jennifer.Baird@PAREXEL.com; or RebeccaPasso of SHIFT Communications, +1-617-681-1217, rpasso@shiftcomm.com, forPAREXEL International
Web site: http://www.parexel.com//
